Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 15

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 15
---
 with the SEC may contain amended and updated discussions of significant risks. We cannot predict future risks or estimate the extent to which they may affect our financial performance.

Risks Related to This Offering

We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.

We currently intend to use the net proceeds of
this offering, if any, for general corporate purposes, which may include working capital, capital expenditures, repayment and refinancing
of debt, research and development expenditures, acquisitions of additional companies or technologies, and investments. This expected use
of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and
timing of our actual expenditures may vary significantly depending on numerous factors. Because of the number and variability of factors
that will determine our use of the proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. As a result, we will retain broad discretion over the allocation of the net proceeds from this offering and could spend the proceeds
in ways that do not necessarily improve our operating results or enhance the value of our common stock. See “Use of Proceeds.”

You may experience immediate and substantial dilution.

The offering price per share in this
offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming the sale
of 9,569,377 shares of our common stock in this offering in the aggregate amount of $20,000,000 at an assumed offering price of
$2.09 per share, which was the last reported sale price of our common stock on Nasdaq on November 14, 2025, and as adjusted net
tangible book value per share of our common stock of $1.48 as of September 30, 2025, you will suffer immediate and substantial
dilution of $0.61 per share representing the difference between our as-adjusted net tangible book value per share as of September 30,
2025 after giving effect to this offering and the assumed offering price. To the extent shares are issued under outstanding options
or warrants, you will incur further dilution. See “Dilution” for a more detailed description of the dilution to
new investors in the offering.

The sale of our common stock in this offering and any future sales of our common stock may depress our stock price and our ability to raise funds in new stock offerings.

We may issue common stock from time to time in
connection with